Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India

Author:

Juneja Shivani1,Rana Proteesh2,Chawla Parvinder3,Katoch Rekha3,Singh Kulvir3,Rana Shobha3,Mittal Tamanna3,Kaur Bhavnish3,kaur Simranjot3

Affiliation:

1. Department of Clinical Pharmacology , Fortis Hospital Mohali , Mohali , India

2. Department of Pharmacology, University College of Medical Sciences , Delhi , India

3. Fortis Hospital Mohali , Mohali , Punjab , India

Abstract

Abstract Objectives The use of Hydroxychloroquine (HCQ) prophylaxis has been recommended by the National task force constituted by the Indian Council of Medical Research (ICMR) for the prevention of corona virus disease 2019 (COVID-19) among healthcare workers (HCWs). However, this recommendation was based essentially on the preclinical data and limited clinical experience. The aim of this study was to evaluate the efficacy and safety of HCQ as a pre-exposure prophylaxis for COVID-19 infection among Indian HCWs. Methods A cross-sectional study was conducted among HCWs of a tertiary care hospital in north India. The HCQ prophylaxis was initiated among 996 HCWs and they were followed up to 8 weeks for conversion to COVID-19 positive status and any adverse drug reaction (ADR). Results About 10.3% of the study participants were tested positive for COVID-19 which was comparable to the positivity rate among HCWs not taking HCQ prophylaxis (9.7%). Conclusions HCQ was well tolerated at a weekly dose of 400 mg for 8 weeks but provided no additional benefit in prevention of COVID-19 among HCWs.

Publisher

Walter de Gruyter GmbH

Subject

Drug Discovery,Pharmacology,General Medicine,Physiology

Reference14 articles.

1. COVID19 state wise status. Government of India. Available from: https://www.mygov.in/corona-data/covid19-statewise-status [Accessed 27 Jun 2020].

2. Recommendation for empiric use of hydroxy-chloroquine for prophylaxis of SARS-CoV-2. Indian Council for Medical Research 2020. Available from: https://icmr.nic.in/sites/default/files/upload_documents/HCQ_Recommendation_22March_final_MM_V2.pdf [Accessed 24 Apr 2020].

3. Gio, J, Tian, Z, Yang, X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3.

4. Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for COVID-19 infection. Available from: https://www.mohfw.gov.in/pdf/RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf [Accessed 24 Apr 2020].

5. Ferner, RE, Aronson, JK. Chloroquine and hydroxychloroquine in COVID-19. BMJ 2020;369:1432. https://doi.org/10.1136/bmj.m1432.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3